*Current Status of Stem Cell Therapy for Sepsis and Acute Respiratory Distress Syndrome DOI: http://dx.doi.org/10.5772/intechopen.86108*

Several pharmaceutical companies hold a number of stem cell lines and work to advance in cell therapies. Finding new culture mediums that able to maintain or differentiate into the desired cell type with high throughput and also diminish the risk of causing cancer is quite difficult. Afterwards, the laboratories and the companies will need to implement several protocols to work under good manufacturing practice guidelines (GMP) and follow specific storage rules of products that want to be used as a therapy. Several delicate conditions need to be fulfilled for these cells, to be approved by health authorities, and to be used in humans and in clinical trials.

First, we want to review the different cell types, their potential sources, and characteristics and underlie why mainly mesenchymal stem/stromal cells are used for the treatment of sepsis and ARDS. Some pre-clinical studies using induced pluripotent stem cells (iPSC) for the treatment of both syndromes and alveolar type II cells for ARDS treatment also presented some interesting results. The different cell subsets are summarized in **Table 1.**
